AbbVie Patient Finder Suitability Analysis
Ada Cockpit - March 2026
Executive Summary
Analysis Scope: Evaluation of AbbVie's drug portfolio for Ada Patient Finder across In-Market Finder (commercialized drugs) and Trial Finder (clinical trials). Revenue model: 8-12% of first-year drug revenue per patient found.
Total Addressable Opportunity
At 1% Penetration: $88.4M/year
At 5% Penetration: $442M/year
Combined USA + DACH + Rest of World markets across Tier 1 and Tier 2 drug-indication pairs
Portfolio Summary Table
| Drug |
Indication |
Tier |
Fit Score |
Addressable Undiagnosed (USA) |
Ada Revenue Opportunity (5% Penetration) |
| Skyrizi |
Crohn's Disease |
1 |
9/10 |
59,300 |
$21.3M/year |
| Rinvoq |
Ulcerative Colitis |
1 |
8/10 |
26,400 |
$7.1M/year |
| Skyrizi |
Psoriasis |
1 |
9/10 |
48,000 |
$17.2M/year |
| Rinvoq |
Rheumatoid Arthritis |
2 |
8/10 |
111,750 |
$30M/year |
| Qulipta |
Chronic Migraine Prevention |
2 |
8/10 |
900,000 |
$42.3M/year |
| Ubrelvy |
Acute Migraine |
2 |
7/10 |
1,800,000 |
$54M/year |
| Vraylar |
Schizophrenia / Bipolar |
2 |
5/10 |
1,114,000 |
$45.8M/year |
| Venclexta |
CLL |
3 |
4/10 |
10,500 |
$7.6M/year |
| Botox Therapeutic |
Chronic Migraine |
3 |
3/10 |
Bundled with Qulipta |
- |
| Humira |
Multiple |
NO |
- |
Biosimilar erosion |
Market exit |
| Imbruvica |
CLL / Lymphoma |
NO |
1/10 |
Patent cliff 2026 |
Declining revenue |
| Epkinly |
DLBCL |
NO |
2/10 |
900 |
Too small |
| Elahere |
Ovarian Cancer |
NO |
2/10 |
Ultra-niche |
Minimal undiagnosed |
Top 3 Opportunities (Tier 1)
1. Skyrizi (Crohn's Disease)
Pitch Hook: "Skyrizi just hit $17.6B in sales, but 59,000 Americans with undiagnosed Crohn's disease are still suffering with IBS misdiagnoses. Ada can find them in weeks, not years. Every patient is worth $7,200 to AbbVie and years of relief for the patient."
Market Opportunity:
- USA Addressable Undiagnosed: 59,300 patients
- DACH Addressable: 14,500 patients
- Rest of World: 32,000 patients
- Patient Finder Fee: $7,200 per patient (10% of $72,000 net annual revenue)
- Total Opportunity (USA only at 5% penetration): $21.3M/year
Why This Is a Strong Fit:
- High Diagnostic Delay: Median 2-5 years from symptom onset to diagnosis
- Excellent Ada Surface Ability (8/10): GI symptoms (chronic diarrhea + blood + weight loss) are well-represented in Ada's assessment
- Maximum Company Motivation (10/10): Skyrizi is THE Humira replacement vehicle; immunology = 50% of AbbVie revenue
- Strong Revenue Growth: Skyrizi grew 50% YoY (2024→2025) to $17.56B; Crohn's is ~35% of that
- Long Patent Protection: US exclusivity until 2031-2033
Clinical Profile:
- Common Misdiagnoses: IBS, celiac disease, food intolerance, infectious gastroenteritis
- Who Diagnoses: Gastroenterologists (requires colonoscopy + biopsy)
- Treatment Duration: Chronic/lifelong; biologics for moderate-severe disease
- Skyrizi Position: Second/third-line after conventional therapy or TNF-inhibitor failure
2. Rinvoq (Ulcerative Colitis)
Pitch Hook: "26,000 Americans have undiagnosed ulcerative colitis today - many think it's just IBS. Ada's symptom assessment can identify them before they end up in the ER with severe flare-ups. At $5,400 per patient, that's a $142M annual opportunity for Rinvoq at 5% penetration."
Market Opportunity:
- USA Addressable Undiagnosed: 26,400 patients
- Patient Finder Fee: $5,400 per patient (10% of $54,000 net annual revenue)
- Total Opportunity (USA only at 5% penetration): $7.1M/year
Why This Is a Strong Fit:
- Strong Symptom Detection (8/10): Blood in stool + diarrhea + urgency = clear IBD signal
- High Company Motivation (9/10): Rinvoq is the second pillar of immunology strategy post-Humira
- Revenue Growth: $8.30B global (2025), growing 35%+ YoY
- Medicare Negotiations = Volume Need: Rinvoq selected for price negotiations; need to maximize patient volume
3. Skyrizi (Psoriasis)
Market Opportunity:
- USA Addressable Undiagnosed: 48,000 patients (moderate-to-severe psoriasis)
- Patient Finder Fee: $7,150 per patient
- Total Opportunity (USA only at 5% penetration): $17.2M/year
Why Pursue:
- Large Revenue Base: $10.5B USA psoriasis revenue (2025)
- Visible Symptoms: Easy for patients to self-identify and describe
- Same Drug as Crohn's: Bundle opportunity with Crohn's patient finding
Tier 2 Opportunities (Pursue)
4. Rinvoq (Rheumatoid Arthritis)
- Addressable Undiagnosed (USA): 111,750 patients
- Opportunity (5% penetration): $30M/year (USA only)
- Key Driver: 33% underdiagnosis rate in US RA population
- Challenge: Moderate Ada surface (6/10) - distinguishing inflammatory RA from osteoarthritis
5. Qulipta (Chronic Migraine Prevention)
- Addressable Undiagnosed (USA): 900,000 patients
- Opportunity (5% penetration): $42.3M/year (USA only)
- Strong Fit: Excellent migraine symptom detection (8/10 Ada surface)
- DTC-Aligned: AbbVie already investing in migraine awareness campaigns
6. Ubrelvy (Acute Migraine Treatment)
- Addressable Undiagnosed (USA): 1.8M patients (undertreated acute migraine)
- Opportunity (5% penetration): $54M/year (USA only)
- Bundle Opportunity: Same patient population as Qulipta (prevention vs acute use cases)
- Lower Per-Patient Value: PRN dosing = $600 PF fee (vs $940 for Qulipta)
7. Vraylar (Schizophrenia / Bipolar Depression)
- Addressable Undiagnosed (USA): 1.1M patients (combined schizophrenia + bipolar)
- Opportunity (5% penetration): $45.8M/year (USA only)
- Major Challenge: Low Ada surface (4.5/10) due to psychiatric symptoms, insight impairment
- Position as Experimental: Test psychiatric patient finding in limited pilot
- Urgency: Patent expiry 2029 = only 3 years left for branded revenue
Key Strategic Recommendations
- Lead with Immunology Portfolio (Skyrizi Crohn's + Rinvoq UC)
- Highest strategic priority for AbbVie (Humira replacement strategy)
- Combined Tier 1 opportunity: ~$50M at 5% penetration
- Perfect alignment with AbbVie's "market expansion" messaging
- Bundle Migraine Portfolio (Qulipta + Ubrelvy)
- Same patient population, different use cases (prevention vs acute)
- Combined $205M opportunity at 5% penetration
- DTC-aligned strategy already in place
- Frame as Market Expansion, NOT Marketing Budget
- Position Patient Finder as finding patients who would NEVER be diagnosed otherwise
- Aligns with AbbVie earnings language: "patient access" and "addressing unmet need"
- Not competing with DTC advertising dollars - complementary strategy
- Acknowledge Psychiatric Limitations (Vraylar)
- Large opportunity on paper ($117M at 5%) but weak fit in practice
- Insight impairment in schizophrenia makes self-assessment difficult
- Position as experimental/pilot with realistic expectations
- Skip Oncology Products Entirely
- Minimal undiagnosed pools due to acute presentations and lab-driven diagnoses
- Venclexta (CLL) has weak fit - asymptomatic, found on bloodwork
- Imbruvica, Epkinly, Elahere all poor candidates
Market Numbers Methodology
All addressable undiagnosed calculations follow a rigorous filtering funnel:
- Total Condition Prevalence: Sourced from epidemiology studies, SEER data, market reports
- Undiagnosed Rate: Applied based on diagnostic delay literature and treatment gap data
- Drug-Addressable Filtering:
- Disease severity (mild vs moderate-severe)
- Line of therapy eligibility (first-line, second-line, etc.)
- Specific drug mechanism appropriateness
- Contraindications and safety exclusions
- Revenue Calculations:
- WAC (Wholesale Acquisition Cost) from manufacturer price lists
- Gross-to-Net estimates: 60-75% depending on therapeutic area
- Patient Finder fee: 10% of first-year net drug revenue per patient
Quality Standards Applied:
- Every number cited with source URL in full analysis document
- Conflicting sources shown with BOTH numbers when discrepancies exist
- Minimum 3 sources per drug for prevalence/revenue claims
- "NOT FOUND" explicitly stated when data unavailable
Geographic Markets
| Market |
Definition |
Notes |
| USA |
United States |
Largest market; ~50-60% of AbbVie global revenue; well-documented epidemiology |
| DACH |
Germany, Austria, Switzerland |
High-value European market; combined 105M population; strong healthcare infrastructure |
| Rest of World |
Western Europe (ex-DACH) |
Primarily UK, France, Spain, Italy, Nordics; ~200M population in addressable markets |
Tier Definitions
| Tier |
Fit Score |
Action |
Criteria |
| Tier 1 |
8-10/10 |
Pursue Aggressively |
High Ada surface ability (7+/10), high company motivation (9+/10), large addressable pool, strong revenue opportunity |
| Tier 2 |
6-7/10 |
Pursue |
Good fit but with some challenges (moderate Ada surface, lower motivation, or smaller pools); still commercially viable |
| Tier 3 |
4-5/10 |
Opportunistic |
Weak fit or structural challenges; pursue only if Tier 1/2 partnership already established |
| NO |
<3/10 |
Skip |
Poor fit, declining revenue, patent cliffs, or minimal undiagnosed pools; do not pursue |
Next Steps for AbbVie Partnership
- Initial Pitch: Lead with Skyrizi Crohn's Disease opportunity
- Highest fit score (9/10)
- Clear diagnostic delay problem that Ada solves
- Aligns with AbbVie's #1 strategic priority
- Proof-of-Concept Pilot: Propose 6-month pilot in USA market
- Target: Find 100-200 undiagnosed Crohn's patients via Ada assessment
- Navigate to gastroenterology consultation + Skyrizi prescription
- Track time-to-diagnosis, conversion rate, physician feedback
- Expansion Path: If pilot successful, expand to:
- Rinvoq (UC + RA) - same immunology franchise
- Migraine portfolio (Qulipta + Ubrelvy) - neuroscience growth segment
- International markets (DACH, then broader Europe)
- Commercial Model: Negotiate pricing structure
- Base fee: 8-10% of first-year net drug revenue per patient found
- Success-based: Only pay for patients who receive prescriptions and meet adherence milestones
- Volume tiers: Reduced % for high-volume programs (>1000 patients/year)